



# CERTIFICATE



This is to certify that the company

## botiss biomaterials GmbH

Hauptstraße 28  
15806 Zossen  
Germany

with the organizational units/sites as listed in the annex

has implemented and maintains a **Quality Management System**.

Scope of certification:

Design and development, production and distribution of products for bone and tissue regeneration.

**-AUS (a), BRA, CND, JPN, USA (a,b,c,d)**

Through an audit, documented in a report, performed by DQS Medizinprodukte GmbH, it was verified that the management system fulfills the requirements of the following standard:

## ISO 13485 : 2016

including applicable country-specific regulatory requirements, as indicated below the scope (full references of abbreviations are listed in the annex)

Certificate registration no. 525421 MDSAP16

Certificate unique ID 170776680

Effective date 2021-10-04

Expiry date 2024-10-03

Frankfurt am Main 2021-10-04



## DQS Medizinprodukte GmbH

Sigrid Uhlemann  
Managing Director

Szymon Kurdyn  
Product Manager

August-Schanz-Straße 21, 60433 Frankfurt am Main,  
Tel. +49 (0) 69 95427-300, [medical.devices@dqs-med.de](mailto:medical.devices@dqs-med.de)

**DQS Medizinprodukte GmbH is recognized under the Medical Devices Single Audit Program.**

Visit <https://www.dqs.de/en/customer-database/> to validate this certificate.



## **Annex to certificate**

**Certificate registration No.: 525421 MDSAP16**

**Certificate unique ID: 170776680**

**Effective date: 2021-10-04**

## **botiss biomaterials GmbH**

Hauptstraße 28  
15806 Zossen  
Germany

### **Audited site**

### **REPs FEI No.: site scope and country-specific requirements**

#### **529022**

**botiss biomaterials GmbH**  
Ullsteinstraße 108, Aufgang D  
12109 Berlin  
Germany

Design and development, production, storage,  
shipment and distribution of products for bone  
and tissue regeneration.

**-AUS (a), BRA, CND, JPN, USA (a,b,c,d)**

**REPs FEI No.: F002292**

#### **525422**

**botiss biomaterials GmbH**  
Hauptstraße 28  
15806 Zossen  
Germany

Design and development, production, storage,  
shipment and distribution of products for bone  
and tissue regeneration.

**-AUS (a), BRA, CND, JPN, USA (a,b,c,d)**

**REPs FEI No.: F001495**



## Annex to certificate

**Certificate registration No.: 525421 MDSAP16**

**Certificate unique ID: 170776680**

**Effective date: 2021-10-04**

## botiss biomaterials GmbH

Hauptstraße 28  
15806 Zossen  
Germany

### Full references of country-specific requirements of MDSAP participating Regulatory Authorities

| Abbreviation | Jurisdiction  | Reference                                                                                                                                                                                                                                |
|--------------|---------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| AUS          | Australia     | (a) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 1 – Full Quality Assurance Procedure<br>(b) Therapeutic Goods (Medical Devices) Regulations 2002, Schedule 3, Part 4 – Production Quality Assurance Procedure |
| BRA          | Brazil        | RDC ANVISA n. 16/2013<br>RDC ANVISA n. 23/2012<br>RDC ANVISA n. 67/2009                                                                                                                                                                  |
| CND          | Canada        | Medical Device Regulations SOR/98-282, Part 1                                                                                                                                                                                            |
| JPN          | Japan         | MHLW Ministerial Ordinance No. 169 (2004) as amended by MHLW Ordinance No. 128 (2014), Articles 4 to 68<br>Japan PMD Act (as applicable)                                                                                                 |
| USA          | United States | (a) 21 CFR Part 803<br>(b) 21 CFR Part 806<br>(c) 21 CFR Part 807<br>(d) 21 CFR Part 820<br>(e) 21 CFR Part 821                                                                                                                          |